VEZUSTEN® - peptide preparation for the treatment of overactive bladder

VEZUSTEN® is the first preparation for pathogenetic course treatment of overactive bladder (OAB). Active ingredient - bladder polypeptides.

Vezusten® is a complex of bladder regulatory peptides that have an organ-/tissue-specific effect on the bladder.

Vezusten® corrects peptide regulation and restores the functional activity of the bladder:

• Reduces hyperreflexivity, normalizing the functional activity of the bladder;
• Restores the evacuation function of the bladder;
• Improves indicators of intravesical pressure and elasticity of the walls of the bladder.

The main symptoms of an overactive bladder are:

• urgent sudden urge to urinate;
• urinary incontinence;
• frequent daytime and/or nighttime urination.

Indication:

treatment of overactive bladder (OAB) in adult patients.

Results of clinical studies:

Vezusten® demonstrates high efficacy and safety, proven in preclinical and clinical studies according to GCP (good clinical practice) standards.

• More than 20% reduction in symptoms according to the TUFS scale.
• 50% or more reduction in the daily number of episodes of urinary incontinence.
• 3 weeks or more, the effect increases after the completion of the course of therapy.

There was a statistically significant decrease in the daily number of urination episodes and a decrease in the degree of anxiety of patients due to OAB symptoms during Vezusten® therapy.

Mode of application:

The preparation is administered intramuscularly, 1 vial per day 3 times a week. The course consists of 10 injections.

The first injectable preparation for the treatment of OAB with a convenient regimen of use and a short course.

The injection method of administration guarantees high bioavailability of the preparation .

Injection administration ensures the safety of use, as the preparation bypasses the gastrointestinal tract, which is especially important for elderly patients.

Ingredients:

1 vial contains polypeptides of the urinary bladder of cattle. - 5.0 mg. (active substance), glycine - 20.0 mg. (excipient:excipient).

Description:

Lyophilizate: lyophilized mass in the form of a tablet, whole, partially or completely crushed white, white with a yellowish tint or yellowish tint.
Reconstituted solution: clear, colorless or slightly yellowish solution.

Direction:

preparation s for the treatment of frequent urination and urinary incontinence.

Action:

Vezusten is a complex of polypeptides isolated from the bladder of cattle.
Vezusten is a peptide regulator that has an organotropic effect on the bladder.
In experiments using organotypic cultures of various tissues of laboratory animals, Vezusten showed tissue-specific activity in relation to bladder tissues, having a stimulating effect on the growth of their cells, while not affecting tissue cultures of other organs.
Preclinical studies indicate the absence of acute and chronic toxicity, Vezusten does not have carcinogenic, embryotoxic, mugagenic, immunotoxic and teratogenic properties, as well as local irritant and allergenic effects.
Experimental studies have shown that the preparation Vesusten has a regulatory effect on the contractile activity of the muscles of the bladder wall and sphincter, relieves
bladder hyperreflexivity.
Conducted clinical studies have shown that the use of the preparation Vezusten relieves the severity of symptoms in patients with overactive bladder (OAB). Due to its pathogenetic action, Vezusten reduces the number of episodes of urinary incontinence, the frequency and urgency of urination, and also has a positive effect on the quality of life of patients with OAB.

Contraindications:

Hypersensitivity to the active substance and / or excipient in the preparation. Age up to 18 years. Pregnancy and the period of breastfeeding.

Use during pregnancy and during breastfeeding:
Due to the lack of clinical data on the safety and efficacy of Vezusten, its use during pregnancy and breastfeeding is contraindicated.

Dosage and administration:

Dosage regimen: Vezusten is administered at a dose of 5 mg (1 bottle) 1 time per day, 3 times a week.

Treatment course is 10 injections.
The need for repeated courses is determined by the attending physician.

In case of missing an injection, it is not recommended to administer a double dose, the next dose of Vezusten is administered at the usual time of the next scheduled day.
Mode of application. The preparation is administered intramuscularly.
Before injection, the contents of the vial are dissolved in 1-2 ml of water for injection or 0.9% sodium chloride solution. When introducing the solvent, the needle should be directed towards the wall of the vial to avoid foaming.

Side effects:

Vezusten has demonstrated a favorable safety profile in clinical trials. Registered adverse reactions associated with the administration of Vezusten were of mild severity and did not require any corrective measures. No cases of serious adverse reactions have been reported.

Best before date:

3 years. Do not use after the expiry date stated on the packaging.

Storage conditions:

at a temperature not exceeding 25 °C

Keep out of the reach of children.

Guaranteed authenticity and quality:

100% original product from PeptidPRO® and SAMSON-MED LLC (Russian Federation)

Development and production:

PeptidPRO®'s area of interest is in the development of preparation s for the pathogenetic treatment of socially significant diseases. The company is currently issuing o the pharmaceutical market three injectable preparation s that significantly affect the quality of life of patients.

Biopharmaceutical company Samson-Med LLC is one of the leaders of the Russian pharmaceutical market in the segment of development, research and production of peptide preparation s. Center for Scientific and Technological Competences.

(Russian Federation)